Last checked at 25 May 2023 12:44
For immediate release | 25 May 2023 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Result of AGM
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, at its Annual General Meeting held earlier today, all the resolutions, as set out in the Notice of Meeting, were duly passed on a poll.
The number of the Group's shares in issue as at the date of the meeting was 540,124,673 ordinary shares of 1p each.
The votes were as follows:
RESOLUTION | VOTES FOR | % | VOTES AGAINST | % | VOTES WITHHELD* | |
1 | Report and Accounts | 219,104,625 | 80.85 | 51,908,041 | 19.15 | 101,986,122 |
2 | Final dividend | 233,018,515 | 62.48 | 139,907,211 | 37.52 | 73,062 |
3 | Elect J. Heper | 264,206,888 | 92.73 | 20,714,828 | 7.27 | 88,077,072 |
4 | Elect M. Sutherland | 233,010,074 | 81.78 | 51,908,621 | 18.22 | 88,080,093 |
5 | Re-elect P. Butterfield | 222,069,893 | 77.94 | 62,848,802 | 22.06 | 88,080,093 |
6 | Re-elect A. Franklin | 264,044,516 | 92.67 | 20,874,179 | 7.33 | 88,080,093 |
7 | Re-elect R. Jones | 201,039,250 | 70.56 | 83,879,445 | 29.44 | 88,080,093 |
8 | Re-elect J. LeCouilliard | 206,081,209 | 77.31 | 60,470,644 | 22.69 | 106,446,935 |
9 | Re-elect K. Neirynck | 253,533,764 | 88.98 | 31,387,952 | 11.02 | 88,077,072 |
10 | Appoint Auditor | 284,909,887 | 99.99 | 7,118 | 0.01 | 88,081,783 |
11 | Remuneration of Auditor | 284,912,231 | 99.99 | 4,328 | 0.01 | 88,082,229 |
12 | Allot shares - general | 179,118, 371 | 62.87 | 105,800,885 | 37.13 | 88,079,532 |
13 | Allot shares - additional | 178,986,132 | 62.82 | 105,933,124 | 37.18 | 88,079,532 |
14 | Disapply pre-emption rights - general | 228,436,470 | 80.18 | 56,483,517 | 19.82 | 88,078,801 |
15 | Disapply pre-emption rights - additional | 228,318,841 | 80.13 | 56,601,146 | 19.87 | 88,078,801 |
The Board notes the votes against Resolutions 2, 5, 7, 8, 12 and 13 and will consult with shareholders to understand their views and publish the results of that consultation in due course.
Chris ChrysanthouGroup General Counsel & Company Secretary25 May 2023
*Each share carries one vote and a 'vote withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the 'votes for' total.
For further information:
Alliance Pharma plc | + 44 (0)1249 466966 |
Cora McCallum, Head of Investor Relations & Corporate Communications | + 44 (0)1249 705168 |
ir@allianceph.com | |
Buchanan | + 44 (0)20 7466 5000 |
Mark Court / Hannah Ratcliff | |
alliancepharma@buchanan.uk.com | |
Numis Securities Limited (Nominated Adviser and Corporate Broking) | + 44 (0)20 7260 1000 |
Freddie Barnfield / Duncan Monteith / Sher Shah | |
Investec Bank plc | + 44 (0)20 7597 5970 |
Corporate Broking: Patrick Robb |
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com